Abstract:Kinesin family member C1 (KIFC1, also known as HSET) is a minus end-directed motor protein, which is critical in centrosome clustering. The present study investigated the expression of KIFC1 in paired hepatocellular carcinoma (HCC) tissues and adjacent non-cancerous tissues from 91 patients by immunohistochemical analysis; clinical data were concomitantly collected. KIFC1 was expressed at high levels in HCC tissues, compared with that in peritumoral tissues (54.9 vs. 14.3%; P<0.01), and its expression correlated with tumor emboli, metastasis, recurrence and time of recurrence. Kaplan-Meier analysis showed that the expression of KIFC1 was significantly associated with tumor-free survival rates. In addition, multivariate analyses revealed that the overexpression of KIFC1was an independent predictive marker in patients with HCC. Consistently, data derived from GEPIA was in agreement with the results. In vitro, KIFC1 knockdown effectively decreased HCC cell viability, and induced apoptosis and cell death. KIFC1 knockdown also significantly suppressed tumor cell migration and invasion in vitro. Mechanistically, the apoptosis-related protein, B-cell lymphoma-2 (Bcl-2), was downregulated in KIFC1 small interfering RNA-treated groups, whereas thee levels of Bcl-2-associated X protein and p53 were upregulated. In addition, the expression levels of phosphorylated phosphoinositide 3-kinase and phosphorylated AKT were decreased significantly when KIFC1 was silenced. The epithelial-mesenchymal transition-related proteins, N-cadherin, matrix metalloproteinase-2 (MMP-2), β-catenin, Slug, and Zinc finger E-box-binding homeobox 1, were downregulated, whereas the expression of E-cadherin was upregulated. The overexpression of KIFC1 was correlated closely with the progression of HCC and poor prognosis, and suggested that the expression levels of KIFC1 are a potential prognostic biomarker and therapeutic target in HCC.

Inhibition of Kinesin Family Member 20B Sensitizes Hepatocellular Carcinoma Cell to Microtubule-Targeting Agents by Blocking Cytokinesis

Inhibition of KIF20A enhances the immunotherapeutic effect of hepatocellular carcinoma by enhancing c-Myc ubiquitination

Kinesin family members KIF2C/4A/10/11/14/18B/20A/23 predict poor prognosis and promote cell proliferation in hepatocellular carcinoma.

Kinesin Family Member C1: Function in liver hepatocellular carcinoma and potential target for chemotherapeutic

The role of kinesin family members in hepatobiliary carcinomas: from bench to bedside

Reducing protein regulator of cytokinesis 1 as a prospective therapy for hepatocellular carcinoma

Kinesin Family Member 18B Activates Mtorc1 Signaling Via Actin Gamma 1 to Promote the Recurrence of Human Hepatocellular Carcinoma

Silencing of KIF2C enhances the sensitivity of hepatocellular carcinoma cells to cisplatin through regulating the PI3K/AKT/MAPK signaling pathway

Kinesin family member 2C aggravates the progression of hepatocellular carcinoma and interacts with competing endogenous RNA.

KIFC1, a Novel Potential Prognostic Factor and Therapeutic Target in Hepatocellular Carcinoma.

Inhibition of KIF22 Suppresses Cancer Cell Proliferation by Delaying Mitotic Exit Through Upregulating CDC25C Expression.

KIF2C: a Novel Link Between Wnt/β-catenin and Mtorc1 Signaling in the Pathogenesis of Hepatocellular Carcinoma

Silencing of KIF18B Restricts Proliferation and Invasion and Enhances the Chemosensitivity of Breast Cancer Via Modulating Akt/GSK‐3β/β‐catenin Pathway

Exploration of inhibitors targeting KIF18A with ploidy-specific lethality

KIFC1 regulated by miR-532-3p promotes epithelial-to-mesenchymal transition and metastasis of hepatocellular carcinoma via gankyrin/AKT signaling

Data from MPHOSPH1: A Potential Therapeutic Target for Hepatocellular Carcinoma

Oncogenic role of kinesin proteins and targeting kinesin therapy.

Inhibition of proliferation and migration of hepatocellular carcinoma by knockdown of KIF3A via NF-κB signal pathway

KIF18A in HCC Metastasis: Dual Role in Anoikis Resistance and Chromosome Instability

Silencing of KNTC1 Inhibits Hepatocellular Carcinoma Cells Progression Via Suppressing PI3K/Akt Pathway

Imatinib inhibits the malignancy of hepatocellular carcinoma by suppressing autophagy